Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...
Immuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
Precision Medicine Online5d
Servier Licenses Black Diamond Therapeutics' RAF-Targeted Solid Tumor Candidate
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
pharmaphorum2d
BioNTech cancer vaccine hits the spot in melanoma
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...
Yahoo Finance6d
Erasca, Inc. (ERAS)
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...
Targeted Oncology5d
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases
The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases. Anti-VEGF therapy with bevacizumab (Avastin) may enhance ...